Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 30, 2021

SELL
$2.07 - $5.1 $25,667 - $63,239
-12,400 Closed
0 $0
Q4 2020

Feb 08, 2021

SELL
$2.24 - $2.87 $3,584 - $4,592
-1,600 Reduced 11.43%
12,400 $28,000
Q3 2020

Nov 12, 2020

SELL
$2.53 - $3.64 $4,807 - $6,916
-1,900 Reduced 11.95%
14,000 $37,000
Q2 2020

Aug 13, 2020

BUY
$1.66 - $3.15 $26,394 - $50,085
15,900 New
15,900 $49,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $73.7M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.